➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Medtronic
Colorcon
Moodys
AstraZeneca

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CARVEDILOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Carvedilol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000294 Effects of Carvedilol on Cocaine Use in Humans - 11 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1998-09-01 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 Effects of Carvedilol on Cocaine Use in Humans - 11 Completed National Institute on Drug Abuse (NIDA) Phase 2 1998-09-01 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00004854 The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure Completed National Center for Research Resources (NCRR) Phase 1 1969-12-31 We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase ejection fraction of the heart under echo. All interpretation of data will be sent to Boston Children's Hospital to be reviewed, which is the primary research center in this study. There are 5 hospitals participating in this study. The population targeted are children with moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome after placing them on Carvedilol is to change their ejection fraction on echo. The patients will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose. Secondary outcome is to increase quality of life, exercise tolerance and decrease their symptom scores as noted on their questionnaires.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carvedilol

Condition Name

Condition Name for Carvedilol
Intervention Trials
Hypertension 22
Heart Failure 20
Healthy 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carvedilol
Intervention Trials
Hypertension 39
Heart Failure 37
Liver Cirrhosis 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carvedilol

Trials by Country

Trials by Country for Carvedilol
Location Trials
United States 386
Japan 36
China 24
Korea, Republic of 18
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carvedilol
Location Trials
New York 22
Texas 18
California 16
Florida 15
Pennsylvania 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carvedilol

Clinical Trial Phase

Clinical Trial Phase for Carvedilol
Clinical Trial Phase Trials
Phase 4 54
Phase 3 29
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carvedilol
Clinical Trial Phase Trials
Completed 70
Recruiting 33
Not yet recruiting 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carvedilol

Sponsor Name

Sponsor Name for Carvedilol
Sponsor Trials
GlaxoSmithKline 23
Institute of Liver and Biliary Sciences, India 6
National Institute on Drug Abuse (NIDA) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carvedilol
Sponsor Trials
Other 191
Industry 56
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
Mallinckrodt
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.